3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Solid Tumor
2
Waldenstrom Macroglobulinemia
1
Sezary Syndrome
1
Sarcoma
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Large Granular Lymphocytic
1
Leukemia, Hairy Cell
1
Intraocular Lymphoma
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Burkitt Lymphoma
1
Interventions
Doxorubicin
80
Ifosfamide
54
Radiotherapy
43
Filgrastim
41
Gemcitabine
38
Cyclophosphamide
34
Etoposide
26
Vincristine
24
Cisplatin
24
Docetaxel
23
pazopanib
21
Trabectedin
19
Carboplatin
17
pembrolizumab
15
Peripheral Blood Stem Cell Transplantation
14
eribulin
12
Mesna
12
Melphalan
12
Sorafenib
11
Sirolimus
11
Irinotecan
11
Granulocyte Colony-Stimulating Factor
11
Bevacizumab
11
Topotecan
10
Paclitaxel
10
Imatinib Mesylate
10
Chemotherapy, Adjuvant
10
pegfilgrastim
9
Temozolomide
9
Surgical Procedures, Operative
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Sarcoma
×
ontuxizumab
×
Clear all
NCT01574716
2019-08-21
SOURCE
Morphotek
Phase 2
Completed
209 enrolled
18 charts